JP2024523514A5 - - Google Patents
Info
- Publication number
- JP2024523514A5 JP2024523514A5 JP2023579198A JP2023579198A JP2024523514A5 JP 2024523514 A5 JP2024523514 A5 JP 2024523514A5 JP 2023579198 A JP2023579198 A JP 2023579198A JP 2023579198 A JP2023579198 A JP 2023579198A JP 2024523514 A5 JP2024523514 A5 JP 2024523514A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- identity
- amino acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110722124.0 | 2021-06-28 | ||
| CN202110722124 | 2021-06-28 | ||
| PCT/CN2022/101780 WO2023274201A1 (zh) | 2021-06-28 | 2022-06-28 | 抗cd40抗体、其抗原结合片段及医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523514A JP2024523514A (ja) | 2024-06-28 |
| JP2024523514A5 true JP2024523514A5 (enExample) | 2025-07-07 |
Family
ID=84690362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579198A Pending JP2024523514A (ja) | 2021-06-28 | 2022-06-28 | 抗ｃｄ４０抗体、その抗原結合断片及び医薬用途 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250340661A1 (enExample) |
| EP (1) | EP4365200A4 (enExample) |
| JP (1) | JP2024523514A (enExample) |
| KR (1) | KR20240026185A (enExample) |
| CN (1) | CN117295764A (enExample) |
| AU (1) | AU2022301422A1 (enExample) |
| BR (1) | BR112023026111A2 (enExample) |
| CA (1) | CA3223842A1 (enExample) |
| MX (1) | MX2023015070A (enExample) |
| TW (1) | TW202309095A (enExample) |
| WO (1) | WO2023274201A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202430226A (zh) * | 2022-12-28 | 2024-08-01 | 大陸商上海盛迪醫藥有限公司 | 抗cd40抗體藥物偶聯物、其製備方法及其醫藥用途 |
| TW202432588A (zh) | 2022-12-28 | 2024-08-16 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種cd40結合分子的組成物及醫藥用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US20030059427A1 (en) * | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| EP1322383B9 (en) * | 2000-10-02 | 2006-09-06 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| ES2551439T5 (es) | 2003-07-01 | 2018-11-08 | Ucb Biopharma Sprl | Fragmentos Fab de anticuerpos modificados |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| EP2535349A1 (en) | 2007-09-26 | 2012-12-19 | UCB Pharma S.A. | Dual specificity antibody fusions |
| CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| HUE049849T2 (hu) * | 2010-03-31 | 2020-10-28 | Boehringer Ingelheim Int | Anti-CD40 antitestek |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| TR201909840T4 (tr) * | 2011-03-11 | 2019-07-22 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antikorları ve kullanımları. |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| WO2016028810A1 (en) * | 2014-08-18 | 2016-02-25 | Biogen Ma Inc. | Anti-cd40 antibodies and uses thereof |
| BR112018004296B1 (pt) * | 2015-09-04 | 2020-05-05 | Primatope Therapeutics Inc | anticorpos anti-cd40 humanizados e usos dos mesmos |
| BR112018006251A2 (pt) * | 2015-09-30 | 2018-10-16 | Janssen Biotech Inc | anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso |
| CN110546164B (zh) * | 2016-11-11 | 2023-10-20 | 锦湖Ht株式会社 | 特异性结合cd40的抗体及其用途 |
| AU2018278051A1 (en) * | 2017-06-01 | 2020-01-30 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof |
| WO2020006347A1 (en) * | 2018-06-29 | 2020-01-02 | Boehringer Ingelheim International Gmbh | Anti-cd40 antibodies for use in treating autoimmune disease |
| CN111454364B (zh) * | 2019-03-04 | 2021-03-02 | 北京天广实生物技术股份有限公司 | 结合cd40的抗体及其用途 |
-
2022
- 2022-06-28 JP JP2023579198A patent/JP2024523514A/ja active Pending
- 2022-06-28 TW TW111124104A patent/TW202309095A/zh unknown
- 2022-06-28 US US18/573,381 patent/US20250340661A1/en active Pending
- 2022-06-28 CA CA3223842A patent/CA3223842A1/en active Pending
- 2022-06-28 BR BR112023026111A patent/BR112023026111A2/pt not_active Application Discontinuation
- 2022-06-28 KR KR1020247001972A patent/KR20240026185A/ko active Pending
- 2022-06-28 AU AU2022301422A patent/AU2022301422A1/en active Pending
- 2022-06-28 CN CN202280034096.6A patent/CN117295764A/zh active Pending
- 2022-06-28 EP EP22832015.6A patent/EP4365200A4/en active Pending
- 2022-06-28 MX MX2023015070A patent/MX2023015070A/es unknown
- 2022-06-28 WO PCT/CN2022/101780 patent/WO2023274201A1/zh not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9840554B2 (en) | Antibodies against platelet-derived growth factor (PDGF) | |
| JP2020528768A5 (enExample) | ||
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| CN103459609A (zh) | TNF-α结合蛋白 | |
| AU2014248636B2 (en) | Humanized anti-N2 antibodies | |
| RU2016145277A (ru) | Антитело против igf-1r и его применение в качестве адресующего переносчика для лечения рака | |
| JP2018510617A5 (enExample) | ||
| AU2019233511B2 (en) | Anti C-MET antibodies | |
| RU2019135404A (ru) | Антитела для лечения инфекции гепатитом в и связанных с ней заболеваний | |
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| JP2024540148A5 (enExample) | ||
| AU2019229663A1 (en) | PD1 binding agents | |
| JP2024523514A5 (enExample) | ||
| RU2018129180A (ru) | Тромбиновое антитело, антиген-связывающий фрагмент и их фармацевтическое применение | |
| WO2022204244A1 (en) | Human ccl28 antibodies | |
| JP2023534779A5 (enExample) | ||
| JP2022548881A5 (enExample) | ||
| US20230406942A1 (en) | Igf1r antibodies | |
| US20260028396A1 (en) | Anti-myostatin antibodies and methods | |
| WO2024088342A1 (en) | Antibodies against cd24 and uses thereof | |
| CN114437215B (zh) | 抗人cd38抗体及其制备方法和用途 | |
| RU2024102543A (ru) | Новые мультиспецифические молекулы | |
| WO2026064762A1 (en) | Anti-myostatin antibodies and methods | |
| AU2026202717A1 (en) | Anti c-met antibodies | |
| RU2021138202A (ru) | Антитела против вируса гепатита в и их применение |